Abstract |
Sixty-six Guatemalan men with parasitologically confirmed cutaneous leishmaniasis, due most commonly to Leishmania braziliensis, were randomly assigned to receive one of three treatment regimens: meglumine antimonate ( meglumine) for 20 days; meglumine for 10 days; and meglumine for 10 days plus alternate-day injections of interferon-gamma. In each group, meglumine was given intravenously as 20 mg of antimony/(kg of body weight.d). All treatment regimens were associated with similar response rates: the lesions of 19 (90%) of 21 patients who received meglumine for 20 days, 18 (90%) of 20 patients who received meglumine for 10 days, and all 22 patients who received meglumine plus interferon-gamma were completely reepithelialized by 13 weeks. In addition, for patients receiving all treatment regimens, test-of-cure cultures for Leishmania were negative and reactivation of lesions did not occur during 12 months of follow-up. The high efficacy of our 10-day course of meglumine indicates that the currently recommended duration of 20 days may be unnecessary for infections caused by L. braziliensis and suggests that a 10-day course of high-dose antimony should be tested as therapy for cutaneous leishmaniasis in other geographic areas.
|
Authors | B A Arana, T R Navin, F E Arana, J D Berman, F Rosenkaimer |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 18
Issue 3
Pg. 381-4
(Mar 1994)
ISSN: 1058-4838 [Print] United States |
PMID | 8011819
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Meglumine
- Interferon-gamma
|
Topics |
- Adolescent
- Adult
- Drug Administration Schedule
- Guatemala
- Humans
- Interferon-gamma
(administration & dosage)
- Leishmaniasis, Cutaneous
(drug therapy)
- Male
- Meglumine
(administration & dosage)
- Recombinant Proteins
|